Cancer Cell Decreased NCOA 5 Causes Glucose Intolerance and HCC Ncoa

Shenglan Gao,1,2 Aimin Li,1,4 Feiye Liu,4 Fengsheng Chen,1,4 Mark Williams,1,3 Chengliang Zhang,1 Zakiya Kelley,1 Chin-Lee Wu,5 Rongcheng Luo,4,* and Hua Xiao1,* 1Department of Physiology, Michigan State University, East Lansing, MI 48824, USA 2Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA 3Cell and Molecular Biology Program, Michigan State University, East Lansing, MI 48824, USA 4Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China 5Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA *Correspondence: luorc01@163.com (R.L.), xiaoh@msu.edu (H.X.) http://dx.doi.org/10.1016/j.ccr.2013.11.005

[1]  Kristen Jepsen,et al.  Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling , 2013, Cell.

[2]  Fanyin Meng,et al.  Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. , 2012, Translational gastrointestinal cancer.

[3]  G. Feng.  Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. , 2012, Cancer cell.

[4]  F. Sung,et al.  Risk of Hepatocellular Carcinoma in Diabetic Patients and Risk Reduction Associated With Anti-Diabetic Therapy: A Population-Based Cohort Study , 2012, The American Journal of Gastroenterology.

[5]  M. Gassmann,et al.  Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells , 2011, Nature Medicine.

[6]  Minshan Chen,et al.  Preoperative levels of serum interleukin-6 in patients with hepatocellular carcinoma. , 2011, Hepato-gastroenterology.

[7]  M. Prentki,et al.  Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents β cell failure in rodent models of type 2 diabetes. , 2011, The Journal of clinical investigation.

[8]  T. Han,et al.  Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. , 2011, Cancer cell.

[9]  K. McGlynn,et al.  The global epidemiology of hepatocellular carcinoma: present and future. , 2011, Clinics in liver disease.

[10]  S. Shoelson,et al.  Type 2 diabetes as an inflammatory disease , 2011, Nature Reviews Immunology.

[11]  T. Hirano,et al.  Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab , 2010, Annals of the rheumatic diseases.

[12]  M. Karin,et al.  NF-κB and STAT3 – key players in liver inflammation and cancer , 2011, Cell Research.

[13]  M. Laudes,et al.  Effects of Inhibition of Interleukin-6 Signalling on Insulin Sensitivity and Lipoprotein (A) Levels in Human Subjects with Rheumatoid Diseases , 2010, PloS one.

[14]  R. Lencioni,et al.  The etiology of hepatocellular carcinoma and consequences for treatment. , 2010, The oncologist.

[15]  Nicholette D. Palmer,et al.  Analysis of candidate genes on chromosome 20q12-13.1 reveals evidence for BMI mediated association of PREX1 with type 2 diabetes in European Americans. , 2010, Genomics.

[16]  P. Meikle,et al.  Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance , 2010, Diabetologia.

[17]  Edward Giovannucci,et al.  Diabetes and Cancer , 2010, Diabetes Care.

[18]  M. Karin,et al.  Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. , 2010, Cancer cell.

[19]  C. Glass,et al.  Macrophages, inflammation, and insulin resistance. , 2010, Annual review of physiology.

[20]  Jun Hee Lee,et al.  Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression , 2010, Cell.

[21]  Paloma Alonso-Magdalena,et al.  The role of oestrogens in the adaptation of islets to insulin resistance , 2009, The Journal of physiology.

[22]  Javier A Menendez,et al.  Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer. , 2009, Clinical chemistry.

[23]  H. El‐Serag,et al.  Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population‐based study of U.S. veterans , 2009, Hepatology.

[24]  Jeong-Ho Kim,et al.  Interleukin-6 and insulin resistance. , 2009, Vitamins and hormones.

[25]  S. Assefa,et al.  Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. , 2008, World journal of gastroenterology.

[26]  A. Alberti,et al.  Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin. , 2008, World journal of gastroenterology.

[27]  Nicholette D. Palmer,et al.  Heterogeneity in gene loci associated with type 2 diabetes on human chromosome 20q13.1. , 2008, Genomics.

[28]  S. Yeh,et al.  Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. , 2008, Gastroenterology.

[29]  J. Girard,et al.  Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. , 2008, The Journal of clinical investigation.

[30]  M. Karin,et al.  The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. , 2008, Trends in molecular medicine.

[31]  A. Lamond,et al.  The nuclear PP1 interacting protein ZAP3 (ZAP) is a putative nucleoside kinase that complexes with SAM68, CIA, NF110/45, and HNRNP-G. , 2007, Biochimica et biophysica acta.

[32]  J. Manson,et al.  A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. , 2007, Archives of internal medicine.

[33]  Michael Karin,et al.  References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S6 Tables S1 to S4 Gender Disparity in Liver Cancer Due to Sex Differences in Myd88-dependent Il-6 Production , 2022 .

[34]  Yaoming Xue,et al.  [Association of serum interleukin-6 and high-sensitivity C-reactive protein levels with insulin resistance in gestational diabetes mellitus]. , 2007, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[35]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[36]  Ronald A. DePinho,et al.  Hepatocellular carcinoma pathogenesis: from genes to environment , 2006, Nature Reviews Cancer.

[37]  S. Akira,et al.  Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. , 2006, Cell metabolism.

[38]  R. Mooney,et al.  Interleukin-6 depletion selectively improves hepatic insulin action in obesity. , 2005, Endocrinology.

[39]  Jenny E Gunton,et al.  Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. , 2005, Cell.

[40]  R. Roeder,et al.  TIP30 Interacts with an Estrogen Receptor α-interacting Coactivator CIA and Regulates c-myc Transcription* , 2004, Journal of Biological Chemistry.

[41]  M. Thun,et al.  Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. , 2004, American journal of epidemiology.

[42]  T. Zimmers,et al.  Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. , 2003, Diabetes.

[43]  W. Coleman,et al.  Mechanisms of human hepatocarcinogenesis. , 2003, Current molecular medicine.

[44]  T. Zimmers,et al.  Suppressor of Cytokine Signaling-3 (SOCS-3), a Potential Mediator of Interleukin-6-dependent Insulin Resistance in Hepatocytes* , 2003, The Journal of Biological Chemistry.

[45]  X. Wang,et al.  TP53 and liver carcinogenesis , 2003, Human mutation.

[46]  E. Keller,et al.  Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. , 2001, The Journal of clinical endocrinology and metabolism.

[48]  F. Sauvé,et al.  CIA, a Novel Estrogen Receptor Coactivator with a Bifunctional Nuclear Receptor Interacting Determinant , 2001, Molecular and Cellular Biology.

[49]  S. Aizawa,et al.  Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. , 2000, Diabetes.

[50]  H. El‐Serag,et al.  Rising Incidence of Hepatocellular Carcinoma in the United States , 1999, Infection Control & Hospital Epidemiology.

[51]  H. El‐Serag,et al.  Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.

[52]  B Stein,et al.  Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta , 1995, Molecular and cellular biology.

[53]  A. Ray,et al.  Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. , 1994, The Journal of biological chemistry.

[54]  N. Nagasue,et al.  Androgen receptor in cirrhotic liver, adenomatous hyperplastic nodule and hepatocellular carcinoma in the human. , 1992, Hepato-gastroenterology.

[55]  T. Libermann,et al.  Activation of interleukin-6 gene expression through the NF-kappa B transcription factor , 1990, Molecular and cellular biology.